Relay Therapeutics’ combination therapy slows breast cancer progression in early trial
Relay Therapeutics said on Monday that interim data from an early trial of its combination breast cancer drug showed it significantly increased patients’ life expectancy without worsening the course of the disease, sending shares up about 37% in early trading.
BELIEBTE BEITRÄGE
Portugal declares risk as wildfires hit the north of the country
September 17, 2024
UK to appoint nature envoy
September 17, 2024
Death tolls rises as Central Europe floods
September 17, 2024
LIVEÜBERTRAGUNG